Beclomethasone/formoterol fixed combination for the management of asthma: Patient considerations

Therapeutics and Clinical Risk Management

Volumn 4, Issue 5, 2008, Pages 855-864

  Nicolini, Gabriele ^a   Scichilone, Nicola ^b   Bizzi, Andrea ^c   Papi, Alberto ^d   Fabbri, Leonardo M ^e  

^a Medical Department   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c University of Ferrara ^*  (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Beclomethasone; Extrafine; Formotertol; Modulite

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE DIPROPIONATE; BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; LONG ACTING DRUG; NORFLURANE; PLACEBO; SALBUTAMOL; STEROID; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ASTHMA; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HUMAN; LOW DRUG DOSE; METERED DOSE INHALER; MONOTHERAPY; MORNING DOSAGE; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; POWDER INHALER; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

EID: 56749121960     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Acerbi D, Brambilla G, Kottakis I. 2007. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology. Pulm Pharmacol Ther, 20:290-303.
2. Allen DB, Mullen M, Mullen B. 1994. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol, 93:967-76.
3. Anderson PJ. 2001. Delivery options and devices for aerosolized therapeutics. Chest, 120(3 Suppl):89S-93S.
4. Barnes PJ. 1995. Inhaled glucocorticoids for asthma. N Engl J Med, 332:868-75.
5. Barnes PJ. 2002. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J, 19:182-91.
6. Bateman ED, Boushey HA, Bousquet J, et al. 2004. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med, 170:836-44.
7. Becker A, Lemière C, Bérubé D, et al. 2005. Summary of recommendations from the Canadian Asthma Consensus guidelines, 2003. CMAJ, 173(6 Suppl):S3-11.
8. Bonnet-Gonod F, Kottakis I, Ballabio M, et al. 2006a. Superior efficacy of a low daily dose of a new fixed combination of beclomethasone dipropionate/formoterol pMDI compared to increased daily dose of BDP in moderate persistent asthma: a 3 month clinical study (abstract). Eur Respir J, 28(Suppl 50):P1237.
9. Bonnet-Gonod F, Kottakis I, Hofman T, et al. 2006b. Beclomethasone dipropionate/formoterol in a single inhaler improves lung function and clinically meaningful outcomes in moderate to severe asthma (abstract). Eur Respir J, 28(Suppl 50):P1230.
10. Bousquet J, Cantini L. 2002. Clinical studies in asthmatics with a new non-extrafine HFA formulation of beclometasone dipropionate (BDP Modulite). Respir Med, 96(Suppl D):S17-27.
11. British Thoracic Society. 2007. British guideline on the management of asthma. A national clinical guideline. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN).
12. Brocklebank D, Ram F, Wright J, et al. 2001. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess, 5:1-149.
13. Caramori G, Ito K, Papi A, et al. 2006. Interactions between long-acting β2-agonists and glucocorticoids. Drug Discov Today Ther Strateg, 3:261-8.
14. Cazzoletti L, Marcon A, Janson C, et al. 2007. Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol 120:1360-7.
15. Descalzi D, Folli C, Nicolini G, et al. 2008. Anti-proliferative and anti-remodelling effect of beclomethasone dipropionate, formoterol and salbutamol alone or in combination in primary human bronchial fibroblasts. Allergy, 63:432-7.
16. Dhillon S, Keating GM 2006. Beclomethasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler. Drugs, 66:1475-83.
17. Dolovich MB, Ahrens RC, Hess DR, et al. 2005. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest, 127:335-71.
18. Eickelberg O, Roth M, Lörx R, et al. 1999. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem, 274:1005-10.
19. Fabbri LM, Nicolini G, Olivieri D, et al. 2008. Inhaled beclometasone dipropionate/formoterol extrafine fixed combination in the treatment of asthma: evidence and future perspectives. Expert Opin Pharmacother, 9:479-90.
20. Gershman NH, Liu H, Wong HH, et al. 1999. Fractional analysis of sequential induced sputum samples during sputum induction: evidence that different lung compartments are sampled at different time points. J Allergy Clin Immunol, 104:322-8.
21. GINA (Global Initiative on Asthma), National Institutes of Health, National Heart Lung and Blood Institute, NHLBI/WHO Workshop Report. Global strategy for asthma management and prevention. NHLBI/WHO workshop report no. 02-3659, January 1995, updated 2007.
22. Giraud V, Roche N. 2002. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J, 19:246-51.
23. Haahtela T, Tamminen K, Malmberg LP, et al. 2006. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study. Eur Respir J, 28:748-55.
24. Hamid Q, Song Y, Kotsimbos TC, et al. 1997. Inflammation of small airways in asthma. J Allergy Clin Immunol, 100:44-51.
25. Hartung TK, Allbutt H, Dewar M, et al. 2002. Moving from CFC aerosol to HFA aerosol or dry powder inhalers: what do patients think? Respiration, 69:314-9.
26. Hauber H, Taha R, Bergeron C, et al. 2006. Effects of hydrofluoroalkane and dry powder-formulated corticosteroids on sputum inflammatory markers in asthmatic patients. Can Respir J, 13:73-8.
27. Inoue T, Doi S, Takamatsu I, et al. 1999. Effect of long-term treatment with inhaled beclomethasone dipropionate on growth of asthmatic children. J Asthma, 36:159-64.
28. Janssens W, VandenBrande P, Hardeman E, et al. 2008. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 31:78-83.
29. Juniper EF, Price DB, Stampone PA, et al. 2002. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. Chest, 121:1824-32.
30. Leone FT, Fish JE, Szefler SJ, et al. 2003. Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. Chest, 124:2329-40.
31. Mariotti F, Poli G, Acerbi D, et al. 2007 Lung deposition of BDP/ formoterol HFA pMDI in healthy volunteers, asthmatic and COPD patients [abstract]. Poster presented at the VIII UIP National congress, Florence, 4-7 December 2007.
32. McGavin JK, Goa KL, Jarvis B. 2001. Inhaled budesonide/formoterol combination. Drugs, 61:71-8.
33. Molimard M, Martinat Y, Rogeaux Y, et al. 2005. Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide. Respir Med, 99:770-8.
34. NAEPP (National Asthma Education and Prevention Program). 2007. Expert Panel Report 3. Guidelines for the Diagnosis and Management of Asthma - Summary Report 2007. J Allergy Clin Immunol, 120(5 Suppl):S94-138.
35. Newman SP. 1990. Metered dose pressurized aerosols and the ozone layer. Eur Respir J. May; 3(5):495-7.
36. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. 2001. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med, 164:1392-7.
37. Osterberg L, Blaschke T. 2005. Adherence to medication. N Engl J Med, 353:487-97.
38. Papi A, Paggiaro PL, Nicolini G, et al. 2007a. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J, 29:682-9.
39. Papi A, Paggiaro PL, Nicolini G, et al. 2007b. Beclomethasone/formoterol versus fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy, 62:1182-8.
40. Partridge MR, van der Molen T, Myrseth SE, et al. 2006. Attitudes and actions of asthma patients on regular maintenance therapy the INSPIRE study. BMC Pulm Med, 6:13.
41. Pedersen S. 2006. Clinical safety of inhaled corticosteroids for asthma in children: an update of long-term trials. Drug Saf 29:599-612.
42. Poli G, Acerbi D, Nollevaux F. 2006. Pharmacokinetics and pharmacodynamics of a new beclomethasone dipropionate and formoterol CFC-free fixed combination in healthy volunteers (abstract). Eur Respir J, 28(Suppl 50):P3869.
43. Poli G, Acerbi D, Rusca A. 2007. Pharmacokinetics and lung bioavailability of Foster using the standard actuator or the Aerochamber Plus spacer (abstract). Eur Respir J, 30(Abstract Suppl):P2117.
44. Prenner BM. 2007. Formoterol dry-powder inhaler for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opin Pharmacother, 8:3069-84.
45. Pritchard JN, Sharma RK. 2001. Introduction: inhaled drug delivery. J Aerosol Med, 14(Suppl 1):S1-2.
46. Profita M, Gagliardo R, Di Giorgi R, et al. 2005. Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics. Allergy, 60:323-9.
47. Rabe KF, Vermeire PA, Soriano JB, et al. 2000. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J, 16:802-7.
48. Rabe KF, Atienza T, Magyar P, et al. 2006. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet, 368:744-53.
49. Rigamonti E, Kottakis I, Pelc M, et al. 2006. Comparison of a new extrafine beclomethasone dipropionate HFA 134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma (abstract). Eur Respir J, 28(Suppl 50):P1236.
50. Roland NJ, Bhalla RK, Earis J. 2004. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest, 126:213-9.
51. Rubin BK. 2004. What does it mean when a patient says, "my asthma medication is not working"? Chest, 126:972-81.
52. Scott MG, Swan C, Wheatley AP, et al. 1999. Identification of novel polymorphisms within the promoter region of the human beta2 adrenergic receptor gene. Br J Pharmacol, 126:841-4.
53. Selroos O, Pietinalho A, Riska H. 1996. Delivery devices for inhaled asthma medication. Clinical implications of differences in effectiveness. Clin Immunother, 4:273-99.
54. Singh D, Piccinno A, Borrill Z, et al. 2008. Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/ formoterol combination inhaler in asthmatic patients. Pulm Pharmacol Ther, 21:551-7.
55. Suissa S, Ernst P, Benayoun S, et al. 2000. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med, 343:332-6.
56. Tarsin WY, Pearson SB, Assi KH, et al. 2006. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. Int J Pharm, 316:131-7.
57. Tulic MK, Christodoulopoulos P, Hamid Q. 2001. Small airway inflammation in asthma. Respir Res, 2:333-9.
58. Van Aalderen WM, Price D, De Baets FM, et al. 2007. Beclometasone dipropionate extrafine aerosol versus fluticasone propionate in children with asthma. Respir Med, 101:1585-93.
59. Vanden Burgt JA, Busse WW, Martin RJ, et al. 2000. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol, 106:1209-26.
60. Van der Palen J, Klein JJ, van Herwaarden CL, et al. 1999. Multiple inhalers confuse asthma patients. Eur Respir J, 14:1034-7.
61. Vastagh E, Kuna P, Calistruc P, et al. 2003. Efficacy and safety of inhaled budesonide delivered once or twice daily via HFA-134a in mild to moderate persistent asthma in adult patients. Comparison with budesonide CFC. Respir Med, 97(Suppl D):S20-8.
62. Virchow JC, Crompton GK, Dal Negro R, et al. 2008. Importance of inhaler devices in the management of airway disease. Respir Med, 102:10-9.
63. Wieshammer S, Dreyhaupt J. 2008. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration, 75:18-25.